Spero Therapeutics (NASDAQ:SPRO) Announces Earnings Results, Misses Expectations By $0.29 EPS

Spero Therapeutics (NASDAQ:SPRO) posted its quarterly earnings results on Thursday. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.29), FiscalAI reports. Spero Therapeutics had a net margin of 24.90% and a return on equity of 16.17%.

Spero Therapeutics Stock Performance

Shares of SPRO stock traded down $0.02 during trading hours on Thursday, reaching $1.00. The company had a trading volume of 328,412 shares, compared to its average volume of 777,181. Spero Therapeutics has a twelve month low of $0.96 and a twelve month high of $3.08. The company has a market capitalization of $58.24 million, a P/E ratio of 9.09 and a beta of 1.59. The stock’s fifty day simple moving average is $1.15 and its 200 day simple moving average is $1.93.

Insider Activity at Spero Therapeutics

In related news, insider Esther Rajavelu sold 40,851 shares of the firm’s stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $1.04, for a total transaction of $42,485.04. Following the sale, the insider directly owned 946,000 shares in the company, valued at approximately $983,840. This trade represents a 4.14% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 2.90% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on SPRO shares. Weiss Ratings upgraded shares of Spero Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday. Compass Point raised shares of Spero Therapeutics to a “neutral” rating in a research report on Monday, September 14th. Zacks Research raised shares of Spero Therapeutics to a “hold” rating in a research note on Monday, September 14th. Wall Street Zen downgraded shares of Spero Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 31st. Finally, Cantor Fitzgerald began coverage on shares of Spero Therapeutics in a report on Wednesday, October 28th. They set an “overweight” rating and a $6.00 target price on the stock. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $6.00.

About Spero Therapeutics

Spero Therapeutics, Inc. (NASDAQ:SPRO) is a biopharmaceutical company focused on developing treatments for multidrug-resistant bacterial infections and certain rare diseases. The company’s research programs are designed to address infections for which existing antibiotics may be inadequate, including complicated urinary tract infections and infections caused by difficult-to-treat pathogens. Spero’s lead product candidate has been tebipenem pivoxil hydrobromide, an orally administered carbapenem antibiotic developed for the treatment of complicated urinary tract infections.